OSIRIS THERAPEUTICS, INC.
|
|
- Cathleen Willis
- 5 years ago
- Views:
Transcription
1 OSIRIS THERAPEUTICS, INC. FORM 8-K (Current report filing) Filed 11/04/08 for the Period Ending 11/04/08 Address 7015 ALBERT EINSTEIN DRIVE COLUMBIA, MD Telephone CIK Symbol OSIR SIC Code Biological Products, Except Diagnostic Substances Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 Copyright 2008, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2008 OSIRIS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.) 7015 Albert Einstein Drive, Columbia, Maryland (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (443) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))
3 Item 1.01 Entry into a Material Definitive Agreement. General. On October 31, 2008, Osiris Therapeutics, Inc. (the Company ) entered into a Collaboration Agreement (the Agreement ) with Genzyme Corp. ( Genzyme ) for the development and commercialization of Prochymal and Chondrogen, two adult stem cell drug candidates in Phase II or III clinical trials for select indications, with significant potential to treat a wide range of diseases. These stem cell drug candidates are designed to provide therapeutic benefits by controlling inflammation, promoting tissue regeneration, and preventing scar formation. Rights. Under the terms of the Agreement, the Company will retain its rights to commercialize Prochymal and Chondrogen in the United States and Canada (the Osiris Territory ), and Genzyme has been granted exclusive rights to commercialize Prochymal and Chondrogen in all other countries, except with respect to Graft vs. Host Disease ( GvHD ) in Japan, where Prochymal has previously been licensed to another (the Genzyme Territory ). Milestone Payments. As partial consideration for the grant of these exclusive rights, the Company will receive a non-contingent, non-refundable payment of $130 million cash from Genzyme, with $75 million paid initially and $55 million to be paid on July 1, The Agreement also provides for contingent milestone payments of up to $1.25 billion in the aggregate, in addition to royalties on any sales by Genzyme, to be paid by Genzyme to the Company, as follows: Prochymal : As respects Prochymal, the Company is eligible to receive up to $500 million in development and regulatory milestone payments and up to $250 million in sales based milestone payments, as follows: Total development milestones related to GvHD of up to $50 million, with $25 million payable upon marketing approval from the United States Food & Drug Administration ( FDA ), and $25 million payable upon marketing approval from the European Medicines Agency ( EMEA ). Total development milestones of up to $180 million related to Crohn s disease and Ulcerative Colitis, with $50 million payable upon achieving statistically significant endpoint(s) in a Phase III clinical trial for Crohn s disease, $100 million payable upon marketing approval by the EMEA for Crohn s disease, $10 million payable upon achieving statistically significant endpoint(s) in a Phase II or Phase III clinical trial for Ulcerative Colitis, and $20 million payable upon achieving marketing approval for Ulcerative Colitis by the EMEA. Total development milestones of up to $270 million related to the development of follow-on indications for Prochymal, with $20 million payable upon each success in a Phase II clinical trial for cardiac, type 1 diabetes or other follow-on indications, as agreed to by the Company and Genzyme, and $40 million payable upon receipt of each marketing approval by the EMEA for Prochymal for chronic obstructive pulmonary disease ( COPD ), cardiac, type 1 diabetes or other follow-on indications, as agreed to by the Company and Genzyme. 2
4 Total sales based milestones of up to $250 million for Prochymal, with $100 million payable when annual Prochymal sales reach $500 million in the Genzyme Territory, and $150 million when annual Prochymal sales reach $1 billion in the Genzyme Territory. Chondrogen : Upon receipt of the results of the planned Phase II/III clinical trial of Chondrogen, Genzyme may elect to opt-out of further Chondrogen development, at which point all rights to Chondrogen will revert to the Company with no further obligations between the companies with regard to Chondrogen. If Genzyme does not opt-out, the Company is eligible to receive up to $500 million in development, regulatory and sales based milestone payments for Chondrogen, as follows: Total development and regulatory milestones of up to $100 million, with $10 million payable if Genzyme does not opt-out, $10 million payable upon demonstration of disease modification in the current clinical trial program, $40 million payable upon marketing approval by either the FDA or EMEA for a pain reduction indication, and $40 million payable upon marketing approval by either the FDA or EMEA for a disease modification indication. Total sales milestones of up to $400 million, with $100 million payable when annual Chondrogen sales reach $500 million in the Genzyme Territory, $150 million when annual Chondrogen sales reach $1 billion in the Genzyme Territory, and $150 million when annual Chondrogen sales reach $2 billion in the Genzyme Territory. Development Costs: The Agreement also provides that the Company will be responsible for ongoing clinical trial costs and future clinical trial costs with respect to both Prochymal and Chondrogen through Phase II clinical trials. The Company and Genzyme will share all costs of future Phase III and Phase IV clinical trials for agreed-upon indications (assuming in the case of Chondrogen that Genzyme does not opt-out), with the Company responsible for 60% of such costs and Genzyme responsible for 40% of such costs. Product Royalties: Assuming successful development and marketing approval, the Company will receive escalating royalties on sales of Prochymal and Chondrogen within the Genzyme Territory. Term: The Agreement provides that it will expire upon the completion of all development plans stipulated in the Agreement and the expiration of all payment obligations; however, Genzyme may terminate the Agreement early and without further obligation at any time after July 1, 2009, and either party may terminate the agreement due to non-performance, material breach or insolvency. Miscellaneous: The Company and Genzyme previously entered into an agreement dated July 26, 2007, establishing a collaborative arrangement for the development of Prochymal for acute radiation syndrome (ARS). In January 2008, the companies were awarded a contract from the U.S. Department of Defense ( DOD ) to develop and supply Prochymal for ARS. The DOD contract is fully valued at up to $224.7 million. 3
5 Risks : The performance by the Company and the ability of the Company to benefit from the Agreement is subject to and presents numerous risks and uncertainties, including the risks and uncertainties described or referred to in the paragraph appearing below. Information presented in this Current Report on Form 8-K may contain forward-looking statements and certain assumptions upon which such forward-looking statements are in part based. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Risks and uncertainties related to the collaborative agreement with Genzyme include, among others: typical business transactional risks; risks related to product development and clinical trial design, performance and completion; uncertainty of the success of Prochymal and Chondrogen in clinical trials and their ability to treat disease; Genzyme early termination and opt-out rights; the ability of Osiris and Genzyme to successfully manufacture and commercialize products; and the uncertainty as to our ability to successfully perform under the collaborative arrangement and earn milestone and royalty payments thereunder. Additional factors that could cause our actual results to differ materially from those anticipated in forward-looking statements, include the factors described in the sections entitled Risk Factors in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission and periodic reports subsequently filed with the United States Securities and Exchange Commission. You should not unduly rely on forwardlooking statements. ITEM 7.01 Regulation FD Disclosure. A copy of the press release dated November 4, 2008, announcing the collaboration agreement with Genzyme described in Item 1.01 of this Current Report on Form 8-K is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference. ITEM 9.01 Financial Statements and Exhibits. (d) Exhibits Press Release dated October November 4, 2008 announcing the collaborative agreement by and between the Registrant and Genzyme Corp. 4
6 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. OSIRIS THERAPEUTICS, INC. Dated: November 4, 2008 By: /s/ PHILIP R. JACOBY, JR. Philip R. Jacoby, Jr. Vice President of Finance (Principal Accounting Officer) 5
7 EXHIBIT INDEX Exhibit No. Description 99.1 Press Release dated November 4, 2008 announcing the collaboration agreement by and between the Company and Genzyme. 6
8 Exhibit 99.1 November 4, 2008 Media Contact, Genzyme Investor Contact, Genzyme Erin Emlock Patrick Flanigan (617) (617) Media Contact, Osiris Investor Contact, Osiris Stacey Holifield Erica Elchin Schwartz Communications (443) (781) Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products CAMBRIDGE, Mass. and COLUMBIA, Md. Genzyme Corp. (Nasdaq: GENZ) and Osiris Therapeutics (Nasdaq: OSIR) announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, latestage adult stem cell treatments that hold significant potential to treat a wide range of diseases. These stem-cell products are designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation. Under the terms of the agreement, Osiris will commercialize Prochymal and Chondrogen in the United States and Canada, and Genzyme will commercialize the treatments in all other countries. Genzyme will make an up-front payment of $130 million to Osiris, plus potential significant milestone and royalty payments. Prochymal is currently being evaluated in two phase 3 trials for graft vs. host disease (GvHD) and one phase 3 trial for Crohn s disease; data from all three trials are expected in It is also being studied in phase 2 trials for type 1 diabetes and chronic obstructive pulmonary disease. A phase 2 trial of Prochymal for acute myocardial infarction and a phase 2/3 trial of Chondrogen for osteoarthritis of the knee are expected to begin soon. Osiris is responsible for the clinical development costs for all ongoing trials, as well as future trials for additional indications through completion of phase 2
9 development. Osiris and Genzyme will share the cost of future Phase 3 and 4 clinical trials, with a 60 percent Osiris / 40 percent Genzyme split. This partnership further strengthens Genzyme s late-stage pipeline of products with the potential to support our growth beyond 2011, stated Henri A. Termeer, Genzyme s chairman and CEO. Osiris is the clear leader in stem cell technology, which holds the promise to transform standards of care in a number of therapeutic areas in which Genzyme already has a strong presence. Today Genzyme and Osiris have forged a powerful partnership in the emerging field of stem cell therapy, said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. This relationship greatly enhances our ability to effectively introduce this groundbreaking technology on a global basis. Strong Strategic Fit The collaboration will leverage Osiris leadership position developing novel stem cell therapies, and Genzyme s regulatory and marketing infrastructure outside of the United States, as well as its expertise commercializing cell therapies. Genzyme developed and commercialized the first-ever cell therapy product approved by the FDA, Carticel (autologous cultured chondrocytes), used in knee cartilage repair. The company also markets MACI (matrix-induced autologous chondrocyte implantation), a second generation version of Carticel, in Australia and Europe, and manufactures Epicel (cultured epidermal autografts), a cell therapy for treating patients with severe burns. Prochymal for GvHD represents a strong strategic fit with Genzyme s existing global transplant franchise, which includes Thymoglobulin (Anti-thymocyte Globulin [Rabbit]), used in the prevention and treatment of acute rejection in kidney transplant patients. Genzyme also expects to launch Mozobil (plerixafor) in the United States and Europe during the first half of next year, following regulatory approvals. Mozobil is intended to enable patients with certain types of cancers to successfully receive a stem-cell transplantation. The potential additional applications for Prochymal align with Genzyme s focus on immune diseases, cardiovascular disease, and endocrinology. Chondrogen complements Genzyme s existing orthopaedics franchise, which includes Carticel, MACI and Synvisc (hylan G-F 20), used to treat pain associated with osteoarthritis of the knee. The planned phase 2/3 trial for Chondrogen will explore the therapy s ability to not only treat osteoarthritic knee pain, but also its potential for disease modification. Genzyme and Osiris last year entered into a collaboration to develop Prochymal for acute radiation syndrome. In January, the companies were awarded a $224.7 million contract from the U.S. Department of Defense to develop Prochymal for this indication. 2
10 Deal Terms Under the terms of the agreement, Genzyme will make a $130 million up-front payment to Osiris, with $75 million paid initially and $55 million to be paid on July 1, In addition, Osiris also has the potential to receive a total of up to $1.25 billion in milestone payments from Genzyme as follows: Osiris is eligible to receive up to $500 million in development and regulatory milestone payments for Prochymal related to GvHD, Crohn s disease, and other potential additional indications that the companies develop together. Based on sales in Genzyme territories, Osiris is eligible to receive up to $250 million in sales milestones for Prochymal as follows: $100 million payable when annual sales reach $500 million and $150 million payable when annual sales reach $1 billion. Based on the results of the planned phase 2/3 trial of Chondrogen, Genzyme may elect to opt-out of further Chondrogen development, at which point all rights to Chondrogen will revert to Osiris with no further obligation by either company. If Genzyme elects to continue with Chondrogen development, Osiris would be eligible to receive up to $100 million in development and regulatory milestones based on the achievement of certain clinical trial results and regulatory approvals. Based on sales in Genzyme territories, Osiris would be eligible to receive up to $400 million in sales milestones for Chondrogen. Osiris is also eligible to receive significant escalating royalties on sales of Prochymal and Chondrogen within Genzyme territories. About Prochymal and Chondrogen Prochymal is a preparation of mesenchymal stem cells (MSCs) formulated for intravenous infusion. Chondrogen is a preparation of MSCs formulated for direct injection into the knee. The MSCs utilized in the products are isolated from the bone marrow of healthy young adult donors. They are grown in culture, permitting large-scale production. Because the cells can be expanded, thousands of doses can be produced from a single donation. Studies suggest MSCs are able to safely facilitate tissue repair through a number of mechanisms. Specifically, these studies have indicated that MSCs are able to down-regulate severe inflammation and work at the cellular level to rebuild damaged tissue through the coordinated release of tissue specific growth factors. In both GvHD and Crohn s disease, Prochymal is being tested in patients who have failed traditional therapies and have few, if any, treatment options remaining. Prochymal has been granted Fast Track status by the FDA for GvHD and Crohn s disease, and is the first stem cell product to receive FDA expanded access approval, making the product available now to children with life-threatening GvHD. It has also been granted Orphan Drug designation by the FDA and EMEA for GvHD. U.S. 3
11 regulatory approval in this indication is anticipated as early as the end of next year; E.U. approval is expected in About Graft vs. Host Disease (GvHD) and Crohn s Disease Both GvHD and Crohn s disease represent major unmet medical needs. GvHD is the most common complication of allogeneic stem cell transplantation, in which functional immune cells in the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. Severe acute steroid-refractory GvHD is fatal in up to 90 percent of cases. Current treatments are marginally effective with significant side effects. Crohn s disease occurs when the immune system attacks the gastrointestinal tract. Autoimmune activity produces inflammation resulting in chronic inflammatory bowel disease. Patients with Crohn s disease have a mortality risk from the disease 50 percent greater than the general population. The disease significantly impacts patients quality of life, and they require ongoing medical, surgical and dietary interventions. About Genzyme One of the world s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme s commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. Genzyme s press releases and other company information are available at and by calling Genzyme s investor information line at within the United States or outside the United States. About Osiris Therapeutics Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn s disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Furthermore, Prochymal is being developed for the repair of heart tissue following a heart attack, the protection of pancreatic islet cells in patients with type 1 diabetes, and the repair of lung tissue in patients with chronic obstructive pulmonary disease. The Company s pipeline of 4
12 internally developed biologic drug candidates under evaluation also includes Chondrogen for arthritis in the knee. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company s technology including 47 U.S. patents each having one or more foreign counterparts. Osiris, Prochymal and Chondrogen are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company s website, (OSIR-G) Genzyme Safe Harbor Statement This press release contains forward-looking statements regarding Genzyme s future business plans and strategies including, without limitation: its expectations regarding launching Mozobil in the U.S. and Europe and the timing thereof; its regulatory plans and expected timetables for collaboration product candidates, including the timing of receipt of data from three Prochymal phase 3 trials in GvHD and Crohn s disease, the anticipatory receipt of regulatory approvals for Prochymal for GvHD in the US in 2009 and in the EU in 2010, and the planned timing for the start of a phase 2 trial for Prochymal for acute myocardial infarction and a phase 2/3 trial for Chondrogen for osteoarthritis of the knee; its expectation that the collaboration with Osiris will support Genzyme s growth beyond 2011; and its assessment of the strategic fit of adult stem cell products with Genzyme s existing business. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the actual timing of the receipt of data from the Prochymal phase 3 trials; Genzyme s and Osiris s ability to accurately design, execute, understand and predict the outcome and impact of the clinical studies related to Prochymal and Chondrogen; the actual efficacy and safety of Prochymal and Chondrogen for treatment of the indications pursued by the collaboration; the actual outcome of submissions to regulatory authorities and the timing of regulatory responses; the ability of Genzyme and Osiris to successfully collaborate together to develop Prochymal and Chondrogen; and the risks and uncertainties described in Genzyme s SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption Risk Factors in Genzyme s Quarterly Report on Form 10-Q for the quarter ended June 30, Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today s date and Genzyme undertakes no obligation to update or revise the statements. Genzyme, Carticel, MACI, Epicel, Thymoglobulin, and Synvisc are registered trademarks and Mozobil is a trademark of Genzyme Corporation. All rights reserved. 5
13 Osiris Safe Harbor Statement This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as anticipate, believe, continue, ongoing, estimate, expect, intend, may, plan, potential, predict, project or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding the following: our product development efforts; our clinical trials and anticipated regulatory requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for MSCs and biologic drug candidates; our cash needs; patents and proprietary rights; ability of our potential products to treat disease; our plans for sales and marketing; our plans regarding our facilities; types of regulatory frameworks we expect will be applicable to our potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled Risk Factors in our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events. # # # 6
Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationAkcea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP. Form: 8-K. Date Filed:
SECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP Form: 8-K Date Filed: 2018-04-23 Corporate Issuer CIK: 927761 Copyright 2018, Issuer Direct Corporation. All Right Reserved. Distribution of
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationAkcea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationVistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter.)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More information20 years. Healed! What did he say? Just got home from the doctor. How s Dad?
2 0 1 2 A N N U A L R E P O R T How s Dad? Just got home from the doctor. What did he say? Healed! 20 years of stem cell research, development, and global leadership distilled into the only word that matters
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationGalena Biopharma, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationPluristem Issues Letter to Shareholders
Pluristem Issues Letter to Shareholders HAIFA, Israel, January 30, 2014 -- Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today issued a
More informationArsanis, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationORGANOVO HOLDINGS, INC.
ORGANOVO HOLDINGS, INC. FORM 8-K (Current report filing) Filed 11/18/14 for the Period Ending 11/16/14 Address 6275 NANCY RIDGE DRIVE SUITE 110 SAN DIEGO, CA 92121 Telephone 858-550-9994 CIK 0001497253
More informationSYNTHETIC BIOLOGICS, INC.
SYNTHETIC BIOLOGICS, INC. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 05/12/14 Address 155 GIBBS STREET SUITE 412 ROCKVILLE, MD 20850 Telephone (734) 332-7800 CIK 0000894158
More informationFORM 8-K. DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationMASTERCARD INC FORM 8-K. (Current report filing) Filed 11/13/02 for the Period Ending 11/13/02
MASTERCARD INC FORM 8-K (Current report filing) Filed 11/13/02 for the Period Ending 11/13/02 Address 2000 PURCHASE STREET PURCHASE, NY 10577 Telephone 9142492000 CIK 0001141391 Symbol MA SIC Code 7389
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event
More informationTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
February 27, 2017 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Key Program Milestones Anticipated in 2017 and 2018 DUBLIN, Feb. 27,
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationASX Small to Mid Caps Conference Singapore. May 27 th, 2010
ASX Small to Mid Caps Conference Singapore May 27 th, 2010 Mesoblast Capital Overview Fund Raisings $m IPO @ 50 cents 21.0 Equity Placements: Jul-06 17.4 Dec-07 13.4 Apr-09 10.8 May-10 37.0 Option funds
More informationARADIGM CORP FORM 8-K. (Current report filing) Filed 08/29/13 for the Period Ending 08/27/13
ARADIGM CORP FORM 8-K (Current report filing) Filed 08/29/13 for the Period Ending 08/27/13 Address 3929 POINT EDEN WAY HAYWARD, CA 94545 Telephone 5102659000 CIK 0001013238 Symbol ARDM SIC Code 3845 -
More informationQUADRANT 4 SYSTEM CORP
QUADRANT 4 SYSTEM CORP FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/05/14 Address 2850 GOLF ROAD, SUITE 405 ROLLING MEADOWS, IL 60008 Telephone 732-798-3000 CIK 0000878802 Symbol
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationATHERSYS CORPORATE FACT SHEET WINTER 2018 NASDAQ: ATHX
ATHERSYS CORPORATE FACT SHEET WINTER 2018 Athersys () is an international biotechnology company that is focused in the field of regenerative medicine. We are committed to the development of innovative
More informationA Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited
A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationFORM 8-K. SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter)
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationLearning Tree International, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More information3M CO FORM 8-K. (Current report filing) Filed 07/23/03 for the Period Ending 07/21/03
3M CO FORM 8-K (Current report filing) Filed 07/23/03 for the Period Ending 07/21/03 Address 3M CENTER BLDG. 220-11W-02 ST PAUL, MN 55144-1000 Telephone 6517332204 CIK 0000066740 Symbol MMM SIC Code 3841
More informationINTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More information2014 Annual and Special Meeting of Shareholders May 7, Roberto Bellini President and Chief Executive Officer
2014 Annual and Special Meeting of Shareholders May 7, 2014 Roberto Bellini President and Chief Executive Officer Twitter: @rbellini Key Strengths Late stage and diversified product portfolio Fully funded
More informationMobiquity Technologies, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Mobiquity Technologies, Inc. Form: 8-K Date Filed: 2012-03-13 Corporate Issuer CIK: 1084267 Symbol: MOBQ Fiscal Year End: 12/31 Copyright 2014, Issuer Direct
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationALLIANCE DATA SYSTEMS CORPORATION (Exact Name of Registrant as Specified in Charter)
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported):
More informationARCUSBIOSCIENCES,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,DC20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d) ofthesecuritiesexchangeactof1934 DateofReport(Dateofearliesteventreported):May9,2018 ARCUSBIOSCIENCES,INC.
More informationTETRA Technologies, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event
More informationSpecial Issue. Mesoblast Limited
Overview is an Australian biotechnology company committed to the commercialization of novel treatments for orthopedic conditions by using its unique adult stem cell technology for the regeneration and
More informationLeading the world in the development of adult stem cell therapies. June 2014
Leading the world in the development of adult stem cell therapies June 2014 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following the presentation,
More informationSCM Lifescience COMPANY PROFILE BUSINESS AREAS. [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea [Website]
SCM Lifescience [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea 22332 [Website] http://www.scmlifescience.com COMPANY PROFILE [Industry] SCM Lifescience is a research-based biopharmaceutical company
More informationSPHERIX INCORPORATED (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationInvestor Presentation
Investor Presentation 2016 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationSPHERIX ANNOUNCES 2009 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES 2009 FINANCIAL RESULTS BETHESDA, MD, April 1, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator in biotechnology
More informationSevion Therapeutics, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Sevion Therapeutics, Inc. Form: 8-K Date Filed: 2017-06-28 Corporate Issuer CIK: 1035354 Copyright 2017, Issuer Direct Corporation. All Right Reserved. Distribution
More information2016 Summary Financial Results
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE -------------------------------------------------------------------------------------------------- GENETIC-AF Phase
More informationForm 8-K. Sally Beauty Holdings, Inc. - SBH. Filed: December 19, 2006 (period: December 19, 2006)
THE FOLLOWING INFORMATION, DOCUMENT OR REPORT IS BEING MADE AVAILABLE BY SALLY HOLDINGS LLC TO THE HOLDERS OF ITS 9.25% SENIOR NOTES DUE 2014 AND ITS 10.5% SENIOR SUBORDINATED NOTES DUE 2016 AS WELL AS
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationDeutsche Bank Health Care Conference
Deutsche Bank Health Care Conference May 8, 2018 NASDAQ: ANIK0 Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationFor personal use only
Quarterly Cash Flow Report June 2016 Perth, Australia; 29 April 2016: Orthocell Limited s Quarterly Cash Flow Report for the quarter ended 30 June 2016 is attached. Orthocell is a commercial-stage, regenerative
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K/A MICROCHIP TECHNOLOGY INCORPORATED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 8, 2016 (April 4, 2016) Date
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Jefferies Global Healthcare Conference June 4, 2015 Safe Harbor Statement The statements made in this presentation that are not statements of historical fact are forward looking
More informationMarch 13, Dear Shareholder:
15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 March 13, 2017 Dear Shareholder: We would like to take this time to report on the business activities and accomplishments of RegeneRx in
More information-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise --
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies -- Sarepta
More informationFORM 8-K. MCORPCX, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 1, 2017 ( February1,2017)
More informationAURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March
More informationBuilding on our specialty expertise. Shire acquires Transkaryotic Therapies Inc.
Building on our specialty expertise Shire acquires Transkaryotic Therapies Inc. "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not
More informationBecoming a Next Generation Stem Cell Company
Becoming a Next Generation Stem Cell Company Dr Ross Macdonald, CEO, Eco Quest AGM, 29 October 2013 Important information This presentation has been prepared by Eco Quest Limited. ( Eco Quest or the Company
More informationSage Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationEagle Pharmaceuticals NASDAQ: EGRX
Eagle Pharmaceuticals NASDAQ: EGRX Scott Tarriff, CEO David Riggs, CFO June 2015 Forward Looking Statements This presentation contains certain forward-looking information about Eagle Pharmaceuticals that
More informationCURTISS WRIGHT CORP. FORM 8-K/A (Unscheduled Material Events) Filed 12/12/2002 For Period Ending 10/29/2002
CURTISS WRIGHT CORP FORM 8-K/A (Unscheduled Material Events) Filed 12/12/2002 For Period Ending 10/29/2002 Address 1200 WALL ST W LYNDHURST, New Jersey 07071 Telephone 201-896-8400 CIK 0000026324 Industry
More informationVital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused
More informationNasdaq: MBRX. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
Nasdaq: MBRX Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 November 14, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationJapan : Victoria Business Forum
Japan : Victoria Business Forum Silviu Itescu Chief Executive 25 August 2015 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following the
More informationBioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
November 9, 2018 BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ( BTI ) (Nasdaq:
More informationTo our fellow shareholders,
BIOCARDIA, INC. To our fellow shareholders, Another year is completed and I remain optimistic about the strength of our therapeutic programs and the progress we are making. There is intense effort being
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Canaccord Genuity 34th Annual Growth Conference August 14 th, 2014 Safe Harbor Statement The statements made in this presentation, which are not statements of historical fact,
More informationEXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017
EXANE Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris June 13, 2017 Forward Looking Statements This presentation contains forward-looking statements as defined in the
More informationMobiquity Technologies, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Mobiquity Technologies, Inc. Form: 8-K Date Filed: 2011-10-03 Corporate Issuer CIK: 1084267 Symbol: MOBQ Fiscal Year End: 12/31 Copyright 2014, Issuer Direct
More informationMobiquity Technologies, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Form: 8-K Date Filed: 2013-09-20 Corporate Issuer CIK: 1084267 Symbol: MOBQ Fiscal Year End: 12/31 Copyright 2014, Issuer Direct Corporation. All Right Reserved.
More informationFor personal use only
2014 Results & Corporate strategy Focus on late stage product development 26 August 2014 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or
More informationPfizer Completes Acquisition of Hospira
For immediate release: September 3, 2015 Media Contact: Joan Campion (212) 733-2798 Investor Contact: Chuck Triano (212) 733-3901 Pfizer Completes Acquisition of Hospira Creates a leading Global Established
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationSanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care
Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care January 22, 2018 Forward Looking Statements This presentation contains forward-looking statements.
More informationARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationJefferies Healthcare Conference 2016
Jefferies Healthcare Conference 2016 Forward looking Statement This presentation concerning Pluristem Therapeutics may include forward-looking statements which represent Pluristem Therapeutics' expectations
More informationMustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY November 13, 2018 Mustang Bio, Inc. ( Mustang ) (NASDAQ: MBIO), a company focused on the development
More informationUTILICRAFT AEROSPACE INDUSTRIES, INC.
UTILICRAFT AEROSPACE INDUSTRIES, INC. FORM 8-K (Current report filing) Filed 02/11/13 for the Period Ending 02/11/13 Address 401 RYLAND STREET, SUITE 200-A RENO, NV, 89502 Telephone 612-615-9334 CIK 0001334740
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationAravive s Lead Drug Candidate - AVB-S6-500
Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics - Tolerability and proof-of-mechanism for lead
More informationUNITED STATES SECURITIES AN D EXCHANGE COMMISSION Washington, D.C FORM SD
UNITED STATES SECURITIES AN D EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (Exact name of the registrant as specified in
More informationCURTISS WRIGHT CORP. FORM 8-K (Unscheduled Material Events) Filed 8/2/1999 For Period Ending 12/31/1999
CURTISS WRIGHT CORP FORM 8-K (Unscheduled Material Events) Filed 8/2/1999 For Period Ending 12/31/1999 Address 1200 WALL ST W LYNDHURST, New Jersey 07071 Telephone 201-896-8400 CIK 0000026324 Industry
More informationRegulatory Challenges for the Development of Allogeneic Mesenchymal Stem Cell Products. Rod Monroy, Ph.D. Director, Prochymal
Regulatory Challenges for the Development of Allogeneic Mesenchymal Stem Cell Products Rod Monroy, Ph.D. Director, Prochymal Safe harbor This presentation contains, and answers given to questions that
More informationVONAGE HOLDINGS CORP.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K. Stamps.com Inc.
OMB APPROVAL OMB Number: 3235-0060 Expires: May 31, 2000 Estimated average burden hours per response...5.00 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
More information